Afamelanotide (Scenesse) for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP)

Record ID 32018001088
Authors' objectives: To assess clinical and cost effectiveness.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Scotland, United Kingdom
MeSH Terms
  • Protoporphyria, Erythropoietic
  • alpha-MSH
  • Dermatologic Agents
  • Drug Implants
  • Sunlight
Organisation Name: Scottish Medicines Consortium (SMC)
Contact Address: Delta House | 50 West Nile Street
Contact Name: Susan Downie
Contact Email:
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.